Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma.
Goteri
Gaia
G
Rupoli
Serena
S
Tassetti
Angela
A
Pulini
Stefano
S
Morichetti
Doriana
D
Filosa
Alessandra
A
Mandolesi
Alessandra
A
Veccia
Salvatore
S
Leoni
Pietro
P
Bearzi
Italo
I
D000368:Aged; D000074323:Alemtuzumab; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003106:Colon / Q000382:microbiology / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced / Q000209:etiology / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000473:pathology; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D008297:Male; D013997:Time Factors
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab